The Next Generation of Liposome Delivery Systems: Recent Experience With Tumor-Targeted, Sterically-Stabilized Immunoliposomes and Active-Loading Gradients

Abra, R.M.; Bankert, Richard B.; Chen, Fa; Egilmez, Nejat K.; Huang, Kaihong; Saville, Renee; Slater, James P.; Shimada, Masahiko; Yokota, Soichiro

doi:10.1081/lpr-120004770

Cited by 67 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have documented improved therapeutic efficacy of LTLs targeted against internalizing antigens or receptors compared to non-targeted liposomes [15,18,20,29,35]. Also, a recent study demonstrated that a Stealth ® liposomal formulation of cisplatin, which lacked efficacy in pilot clinical studies, gave good therapeutic results when delivered in an immunoliposome that was targeted to an internalizing antigen [19]. In other studies, LTLs did not show improved therapeutic efficacy over non-targeted liposomal drugs, which was attributed to the lack of internalization of LTLs into the cells [36,37].…”

Section: B Internalizing Versus Non-internalizing Antigensmentioning

confidence: 97%

“…The ligands promote the selective binding of the liposomes to tumor-associated antigens or receptors and facilitate the delivery of the drug-liposome packages to the cellular site of drug action. Targeting moieties can include: monoclonal antibodies (mAbs) or antibody fragments, peptides, growth factors, carbohydrates, glycoproteins, or receptor ligands [14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: B Ligand-mediated Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Ligand-Targeted Liposomes for Cancer Treatment

Sapra

Tyagi²,

Allen

2005

CDD

233

138

View full text Add to dashboard Cite

Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.

show abstract

Section: B Internalizing Versus Non-internalizing Antigensmentioning

confidence: 97%

Section: B Ligand-mediated Targetingmentioning

confidence: 99%

Ligand-Targeted Liposomes for Cancer Treatment

Sapra

Tyagi²,

Allen

2005

CDD

233

138

View full text Add to dashboard Cite

show abstract

“…On the other hand, the coupling of targeting moieties to the surface of liposomes can promote the selective binding to achieve tissue specificity. Targeting moieties include monoclonal antibodies (mAbs) or antibody fragments, peptides, growth factors, carbohydrates, glycoproteins, or receptor ligands [116][117][118][119][120][121][122][123][124][125][126][127].…”

Section: Modified and Targeted Lipoplex Deliverymentioning

confidence: 99%

Intracellular Trafficking, Metabolism and Toxicity of Current Gene Carriers

Kuo¹,

Huang

2009

CDM

View full text Add to dashboard Cite

Gene delivery remains to be a very challenging field to efficiently transport the therapeutic gene and to modulate proteins with the desired function at the target site. The physiochemical and biological barriers are the major hurdles that need to be considered, particularly when administered systematically, in order to optimize the therapeutic efficacy. Numerous modifications have been extensively investigated aiming to provide protection from the plasma degradation, enhancement of transfection, target specificity, and most importantly, minimizing the side effects such as cellular toxicity and immune response. This article provides a review with respect to the in vitro and in vivo toxicity, as well as cellular and physiological interactions with the gene delivery system composed from viral vectors, cationic lipids and polymers. Recent progress and development are also addressed, with promising results that may be further adopted for clinical use.

show abstract

“…Antibody and their fragments are the most widely explored targeting moieties which can be easily anchored to liposomal surface without alteration of liposome integrity and the antibody properties (Torchilin, 1985). Immunoliposomes directed by monoclonal antibodies are promising vehicles for tumor targeted drug delivery (Abra et al, 2002;Kim et al, 2008). To further enhance the efficacy and cytosolic release of encapsulated content pH-sensitive immunoliposomes have been developed which are taken up by the target cell by ligand mediated endocytosis and upon internalization they fuses with the endosomal membrane at low pH.…”

Section: The Ph-sensitive Immunoliposomesmentioning

confidence: 99%

A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery

2014

View full text Add to dashboard Cite

The pH-sensitive liposomes have been extensively used as an alternative to conventional liposomes in effective intracellular delivery of therapeutics/antigen/DNA/diagnostics to various compartments of the target cell. Such liposomes are destabilized under acidic conditions of the endocytotic pathway as they usually contain pH-sensitive lipid components. Therefore, the encapsulated content is delivered into the intracellular bio-environment through destabilization or its fusion with the endosomal membrane. The therapeutic efficacy of pHsensitive liposomes enables them as biomaterial with commercial utility especially in cancer treatment. In addition, targeting ligands including antibodies can be anchored on the surface of pH-sensitive liposomes to target specific cell surface receptors/antigen present on tumor cells. These vesicles have also been widely explored for antigen delivery and serve as immunological adjuvant to enhance the immune response to antigens. The present review deals with recent research updates on application of pH-sensitive liposomes in chemotherapy/ diagnostics/antigen/gene delivery etc.

show abstract

The Next Generation of Liposome Delivery Systems: Recent Experience With Tumor-Targeted, Sterically-Stabilized Immunoliposomes and Active-Loading Gradients

Cited by 67 publications

References 2 publications

Ligand-Targeted Liposomes for Cancer Treatment

Ligand-Targeted Liposomes for Cancer Treatment

Intracellular Trafficking, Metabolism and Toxicity of Current Gene Carriers

A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery

Contact Info

Product

Resources

About